RE:RE:RE:Worth a Buy Yet?HEXO PS-Ratio with historical data and sector comparisons
https://ycharts.com/companies/HEXO.TO/ps_ratio
quinlash wrote: HEXO has the lowest PS-Ratio when compared to Canopy and Tilray, they also have the lowest sharecount. HEXO has multiple agreements with Molson. They also have on-going sales within the US through the Molson JV. They have a supply agreement overseas and working on Germany with plans to Poland and a mention of possible interest in starting to expand into Cali.
Upcoming QTR report will show additional sales over and beyond anything they have posted over the last couple of years as they will be reporting additional sales from Zenabis, the Dec report will have sales from 48 North and Redecan added to those figures.
I trust that no later than Dec the market is going to get a firm slap up the side of the head as to exactly how undervalued and under-appreciated this stock really is.
JMHO
Q
quinlash wrote: Management has actually been doing a good job IMHO but I am judging that based on the progress they are making with such things as; product rollouts, partnerships and expansion of the business into new markets... definately not using the SP as a basis for my own assessement of the management team.
As for capitial raise etc, the company, like all the major players, is not profitable at this point so until they turn cash flow positive they may at times need to raise more money to fund new expansion, new products etc. As long as the capitial raise produces more revenue for the operation at an acceptable margin (HEXO seems to favor 40%) then it's a win for investors who hold long for those incremental revenues to show up on the books.
The biggest challenge most have (again... IMHO) is that they invest thinking they will be rich overnight rather than have the patience for the organization to grow and start producing those stronger QTR reports.
Hope that helps.
Q
CGYY80 wrote:
Haven't held hexo since the Hydropothecary days a few years ago. Redecan revenue puts HEXO up with Canopy and Tilray in terms of revenue, at a fraction of the market cap of the bigger players. My biggest concern is that Sebastian has more tricks up his sleeve to absolutely burn shareholders more so than he's already done - specifically the endless raises and dilution.
I'm conflicted, seems undervalued but I also think the folks at the helm are clueless here. Thoughts?